Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity Academic Article uri icon

Overview

MeSH Major

  • Head and Neck Neoplasms
  • Lung Neoplasms
  • Ovarian Neoplasms
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Although exploratory in nature, this combined pharmacogenomic and pharmacokinetic model helps to define and differentiate the primary determinants of skin and gastrointestinal toxicity of erlotinib. The findings may be of use both in designing trials targeting a particular severity of rash and in considering dose and schedule modifications in patients experiencing dose-limiting toxicities of erlotinib or similarly targeted agents. Further studies of the relationship between germline polymorphisms in EGFR and the toxicity and efficacy of EGFR inhibitors are warranted.

publication date

  • March 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.13.1128

PubMed ID

  • 18309947

Additional Document Info

start page

  • 1119

end page

  • 27

volume

  • 26

number

  • 7